InSilico Medicine's NLRP3 inhibitor ISM8969 has completed IND-enabling studies for the treatment of Parkinson's disease

Zhitong
2025.08.15 00:39

On August 15th, InSilico Medicine Cayman TopCo announced that its oral NLRP3 inhibitor ISM8969, targeting inflammatory and neurodegenerative diseases, has completed IND-enabling studies and obtained positive results, supporting the subsequent clinical validation. Based on the existing data, InSilico Medicine plans to submit a new drug clinical research application in the fourth quarter of this year

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.